Roche Holding AG

06/23/2021 | Press release | Distributed by Public on 06/23/2021 09:52

Chugai obtains regulatory approval for Evrysdi for the treatment of Spinal Muscular Atrophy

Investor Update

Chugai obtains regulatory approval for Evrysdi for the treatment of Spinal Muscular Atrophy

Dear Investor,

Please find attached a press release by Chugai:
https://www.roche.com/210623_IR_Chugai_eEvrysdi_approval.pdf

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: [email protected]

 Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: [email protected]
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected]

 Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected]
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected] 		Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: [email protected]
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected]